Xcout Intel
ADARx Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to ADARx Pharmaceuticals, Inc. among biotechnology companies — ranked by similarity to what ADARx Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see ADARx Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company located in San Diego, California. The company is committed to developing cutting-edge RNA-targeted therapeutics to treat various genetic and severe diseases. ADARx focuses on translating scientific research into life-saving medicines through its proprietary drug discovery pipeline.
ADARx Pharmaceuticals, Inc. at a glance
ADARx Pharmaceuticals, Inc. is a biotechnology company headquartered in United States. It is publicly listed (ADRX) with a market capitalisation of $1.9B. Xcout tracks 18 named people at ADARx Pharmaceuticals, Inc., including Zhen Li (President & CEO).
ADARx Pharmaceuticals, Inc. leadership
- Zhen LiPresident & CEO
- Ryan FiskChief Financial Officer and Chief Business Officer
- Rui ZhuChief Technology Officer
- Rob AcklesChief People Officer
- Robert A. MacLeodChief Scientific Officer
- Yu ChenFounder and Managing Partner of TCGX
12 more named people on record for ADARx Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Recent ADARx Pharmaceuticals, Inc. news
- IPOADARx Pharmaceuticals lève 446 millions de dollars lors d'une introduction en bourse augmentée. - fr.qz.com
- IPOIPO registration (S-1)
- IPOADARx Pharmaceuticals Plans IPO of 21.9M Shares at $15-$17 Each
9 corporate events on record, with sources — see the full timeline →
Top 12 ADARx Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to ADARx Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Adcentrx Therapeutics is a privately held biotechnology company founded in 2021 that focuses on accelerating advanced medical treatments. Its research headquarters are located in San Diego, California.
Similar biotechnology company
Adynxx, Inc. is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, focused on biotechnology research and drug development.
Life Sciences (Therapeutics)
DTx Pharma, Inc. is a privately held biotechnology company based in San Diego, California, that addresses the challenges associated with delivering RNA-based therapeutics.
Similar biotechnology company
Travere Therapeutics is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and delivering life-changing therapies for people living with rare diseases.
Life Sciences
Iris Medicine is an early-stage life sciences and biotechnology company pioneering allele-selective RNA therapies. Headquartered in California, the company develops novel treatments utilizing its proprietary sbRNA technology platform.
Biotech
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Life Sciences
Crystalys Therapeutics is a biotechnology research company headquartered in San Diego, California, dedicated to developing novel therapies to address significant unmet medical needs.
Biotech
Arrowhead Pharmaceuticals, Inc. is a U.S.-based company focused on developing innovative medicines for the treatment of challenging and difficult-to-treat diseases. The company's extensive development pipeline features several RNA interference (RNAi) therapeutic candidates. These include: ARO-AAT: Currently in Phase II clinical trials for liver diseases associated with alpha-1 antitrypsin deficiency. ARO-APOC3: Advancing through both Phase 2b and Phase 3 clinical studies for hypertriglyceridemia. ARO-ANG3: Undergoing Phase 2b clinical evaluation for dyslipidemia. ARO-HSD: Having successfully completed Phase 1/2 clinical trials for various liver diseases. ARO-ENaC2: In preclinical development for dyslipidemia linked to cystic fibrosis. ARO-C3: In Phase 1/2a clinical trials, designed to reduce the production of complement component 3. ARO-DUX4: A preclinical candidate targeting facioscapulohumeral muscular dystrophy. ARO-XDH: In Phase 1 clinical trials for refractory gout. ARO-COV: A preclinical program focused on COVID-19. ARO-RAGE: In Phase 1/2a clinical trials for muco-obstructive or inflammatory pulmonary conditions. ARO-MMP7: Also in Phase 1/2a clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF). Beyond its proprietary programs, Arrowhead is actively involved in the development of other significant therapeutics: JNJ-3989: A subcutaneously administered RNAi therapeutic aimed at chronic hepatitis B virus infection. Olpasiran: Designed to decrease the synthesis of apolipoprotein A. ARO-AMG1: Targeting genetically validated pathways for cardiovascular disease. Arrowhead Pharmaceuticals maintains strategic licensing and research collaborations. It partners with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics JNJ-75220795, ARO-JNJ2, and ARO-JNJ3, all of which target liver-expressed pathways. Additionally, the company has a research and license agreement with Takeda Pharmaceuticals U.S.A., Inc. for an RNAi therapeutic candidate intended for liver disease. Established in 1989, Arrowhead Pharmaceuticals, Inc. operates from its corporate headquarters in Pasadena, California.
Similar biotechnology company
Inmagene Biopharmaceuticals is a clinical-stage biotechnology company headquartered in San Diego, California. The firm is dedicated to the research, development, and advancement of novel therapeutic medicines. It operates within the life sciences sector, focusing on clinical development and corporate mergers.
Similar biotechnology company
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Similar biotechnology company
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia dedicated to developing advanced RNA-based treatments against genetic diseases. The company maintains its headquarters in Paterna and Valencia, Spain.
Similar biotechnology company
Arbor Biotechnologies, Inc. is a next-generation gene editing company focused on discovering and developing precise genetic medicines for rare and complex diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ADARx Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ADARx Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →